FILTER BY SCHOLARAll Scholars
- The following scholars have published material in this field
FILTER BY RELEVANCEMost Recent
FILTER BY CONTENT TYPEAll Content Types
Tanzanian authorities and INTERPOL have just made a major seizure of fake and substandard drugs. While good news, it's a stark reminder that Africa remains ground zero in the global war on bad medicine.
Evidence is mounting that some pharmaceutical manufacturers in countries like India cut corners and send low-quality products to major, developed markets. Worse still, they may have separate production lines for drugs they sell in developing markets like Africa, where poor quality is more likely to go unnoticed.
Substandard and falsified medicines are major global health challenges that cause unnecessary morbidity and mortality around the world and threaten to undermine recent progress against infectious diseases by facilitating the emergence of drug resistance.
In the past decade major problems with Chinese-made food and drugs has led to thousands of deaths, mostly in China itself, but many in rich countries too, including at least 150 deaths in the U.S. from counterfeits of the drug heparin. And while fake drugs are the largest concern for foreigners, within China the greatest fear is over milk formula.
The Indian Supreme Court’s decision on Gleevec will surely help some patients seeking affordable treatment (“US should tighten rules for patenting changes to drugs,” Editorial, April 8), but there is no guarantee that local companies can reproduce a drug that is as safe or effective as the original, especially when they have no data-sharing agreement with the company that designed it.
Poorly manufactured and fraudulent medicines kill thousands of people around the world each year. For infectious diseases like malaria and HIV, shoddy medicines also accelerate drug resistance and dramatically alter the course of epidemics. With few new drugs under development, recent progress against these major killers in the poorest countries is precarious.
The Shadow Financial Regulatory Committee (SFRC) is a group of publicly recognized independent experts on the financial services industry — including experts in banking, insurance, and securities — who meet regularly to study and critique regulatory policies affecting this sector of the economy.
This event has been cancelled due to inclement weather.
At a Capitol Hill luncheon event, Westchester County Executive, Robert Astorino, will present his first-hand experience with HUD's demands to sue localities over common zoning regulations in an effort to dismantle local zoning as it is known today.
AEI's Marilyn Ware Center for Security Studies will host General Mark Welsh III, Chief of Staff of the US Air Force for the concluding session of its series with the Joint Chiefs of Staff.
Join AEI for a discussion of two new policy proposals that address the use of road pricing and public-private partnerships, as well as state efforts to enhance infrastructure and economic competitiveness.
Join AEI for a discussion of professional sports subsidies and — fittingly — for a free lunch.
AEI’s Jeffrey Eisenach will argue in favor of a generic antitrust enforcement model with primary enforcement by the FTC and Jonathan Baker of American University will maintain that an industry-specific regulator like the FCC is needed to work with antitrust enforcers to shape competition in the broadband industry. The debate will be moderated by US Court of Appeals Judge Stephen Williams.